EbV-positive diffuse large cell b-cell lymphoma C83.7

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 01.12.2021

Dieser Artikel auf Deutsch

Synonym(s)

Burkitt's lymphoma; Burkitt's tumor; EBV-associated large cell B lymphoma.; HHV-4-positive diffuse large cell B-cell lymphoma; Lymphoma African Burkitt lymphoma

Definition
This section has been translated automatically.

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is usually an aggressive (highly malignant) non-Hodgkin's lymphoma. DLBCL is the most common subtype of malignant B-cell lymphoma. The EBV-positive variant of diffuse large B-cell lymphoma was detected in 6.9% of cases in a larger study (n=239) of newly diagnosed patients using in situ hybridization.

Occurrence/Epidemiology
This section has been translated automatically.

The incidence of Epstein-Barr Virus (EBV)-positive DLBCL in Asia and Latin America is 8 to 10% (Poston JN et al).

Etiopathogenesis
This section has been translated automatically.

Epstein-Barr virus (EBV) positivity in diffuse large B-cell lymphoma (DLBCL) triggers a crucial oncogenic mechanism to activate intracellular signaling through LMP1 (latent membrane protein 1). LMP1, an Epstein-Bar virus specific protein, acts as a functional CD40 homologue to prevent apoptosis of infected B lymphocytes and promote their proliferation. The protein functions as a constitutively active tumor necrosis factor receptor that induces activation of several signaling pathways, including those of the NF-kappa B family. LMP1 signaling leads to the upregulation of anti-apoptotic proteins and provides growth signals in latently infected cells.

Therapy
This section has been translated automatically.

Therapeutically, successes are described by rituximab , with a similar success as in EBV-negative lymphomas. The median survival time and progression-free survival time of this group was 8.7 and 6.8 months, respectively, after retuximab therapy of patients with EBV-positive DLBL (Sato A et al. 2014).

Note(s)
This section has been translated automatically.

It is striking that the African form is geographically limited to areas where malaria is also endemic (Mawson AR et al. 2017). The fact that the incidence of Burkitt's lymphoma is also significantly lower in those areas of Africa where malaria is repressed shows a close pathogenetic link between the two lymphoma types. The connections have not yet been clarified. However, it has been shown that a malaria attack is associated with a significantly reduced EBV-specific cytotoxicity. Therefore, it seems to be possible that EBV-transformed B-lymphocytes can prolong proliferation.

Literature
This section has been translated automatically.

  1. Poston JN et al (2018) The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Clin Med Insights Blood Disord11:1179545X18762799.
  2. Mawson AR et al (2017) Malaria, Epstein-Barr virus infection and thepathogenesis of
    Burkitt's lymphoma. Int J Cancer 141:1849-1855.

  3. Sato A (2014) Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci 105:1170-1175.

  4. Yoon SE et al (2020) A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Ann Hematol 99:1283-1291.

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 01.12.2021